Core Insights - Esperion Therapeutics has signed a definitive agreement to acquire Corstasis Therapeutics to enhance its cardiovascular portfolio with the addition of Enbumyst, a bumetanide nasal spray approved by the FDA for treating oedema related to congestive heart failure, hepatic, and renal diseases in adults [1][3] Group 1: Acquisition Details - The acquisition involves Esperion purchasing all outstanding stock of Corstasis for an upfront cash payment of $75 million [1] - Corstasis shareholders may receive up to $180 million in additional payments based on regulatory and commercial milestones, along with low double-digit royalties on sales of Enbumyst and any follow-on products [2] - The transaction is expected to conclude in the second quarter of 2026 [2] Group 2: Product Information - Enbumyst is the first FDA-approved nasal spray diuretic, providing a self-administered outpatient option that may bridge the gap between oral and intravenous diuretic therapies for adults with oedema associated with liver disease, kidney disease, or heart failure [3] - Esperion plans to fund the acquisition through its current credit facilities and by monetizing its Japanese royalties via funds managed by Athyrium Capital Management and HealthCare Royalty [3] Group 3: Strategic Vision - Esperion's president and CEO, Sheldon Koenig, stated that this acquisition aligns with the company's long-term Vision 2040 and aims to bring meaningful innovation to patients struggling with diuretic therapy [4] - The integration of Enbumyst into Esperion's commercial platform is expected to drive sustained double-digit growth and strengthen the company's leadership in cardiovascular care [5] - In January 2024, Daiichi Sankyo Europe amended its existing collaboration with Esperion, valued at $125 million, further supporting the company's strategic initiatives [5]